Nearly every compound this publication covers occupies the same regulatory space: sold as a research chemical, studied mostly in animals, with a human evidence base that’s thin, emerging, or entirely absent. Tesamorelin breaks that pattern. Under the brand name Egrifta, it’s been an FDA-approved medication since 2010, with a published Phase 3 trial record behind it — which makes it a useful yardstick for what a fully-evidenced compound in this category actually looks like.

What It Was Actually Approved For

Tesamorelin’s approval is specific and narrower than its community reputation suggests: it’s indicated for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, a fat-redistribution condition linked to antiretroviral therapy. It is not broadly approved as a general fat-loss or anti-aging compound, whatever the marketing framing elsewhere implies.

The Actual Trial Data

The foundational trial, led by Falutz and colleagues and published in the New England Journal of Medicine in 2007, randomized 412 patients with HIV-associated abdominal fat accumulation to daily tesamorelin or placebo for 26 weeks. The primary endpoint — change in visceral adipose tissue measured by CT scan — showed a reduction of roughly 15 to 18 percent versus placebo, a large enough effect to be clearly measurable and clinically meaningful in this population.

A subsequent pooled analysis across two Phase 3 trials, covering 806 participants, confirmed the effect and added detail: visceral fat dropped while subcutaneous fat was largely unaffected, IGF-1 rose in a pattern consistent with the drug’s GHRH-analog mechanism, and fasting triglycerides improved alongside the fat reduction.

“This is what it looks like when a compound in this category actually clears the bar. It’s the exception, not the norm — which is exactly why it’s worth understanding.”

— a peptide researcher who reviewed the trial literature for this piece

Why This Matters for Reading Everything Else in This Space

Tesamorelin shares its basic mechanism — GHRH receptor activation — with CJC-1295, a compound covered elsewhere in this publication that has a single Phase 1 human trial and no completed efficacy studies. Both stimulate the same pathway. Only one has walked that mechanism all the way through randomized, placebo-controlled Phase 3 trials in a defined population with a defined endpoint.

That gap isn’t a knock on CJC-1295 specifically — it’s the standard pattern across almost this entire compound category. Tesamorelin is the rare case that shows what the far end of that evidence pipeline actually looks like when a compound reaches it.